PCOS stands for polycystic ovary SYNDROME and PCOD stands for polycystic ovarian DISEASE, and the difference between the last two words carries most of the clinical meaning. A syndrome is a defined cluster of features that consistently travel together and have shared underlying biology — in PCOS, the clustering of irregular ovulation, raised male-pattern hormones and polycystic-appearing ovaries on ultrasound, sitting on top of a metabolic spine of insulin resistance. A disease, used in the older sense, points to an end-organ abnormality — in PCOD, the appearance of multiple small follicles on the ovary itself, often without the full surrounding picture.

Internationally and at most modern Indian academic centres the term PCOS has replaced PCOD because it captures the metabolic and hormonal whole rather than the ultrasound part. The official Indian society of obstetricians and gynaecologists (FOGSI), the Indian Council of Medical Research (ICMR) and the Endocrine Society of India all use PCOS. PCOD continues to live on in older textbooks, on private hospital websites, in radiology reports, in patient handouts and in the everyday speech of many practising gynecs, particularly outside the metros. The result is that two women with the same biology can leave two different clinics on the same day carrying two different labels.

A useful working translation is this. When a gynec or radiology report uses PCOD in 2026 India it most often means there are polycystic-appearing ovaries on ultrasound, the cycle is irregular and the rest of the work-up is either pending or has not added up to the full syndrome yet. When the same setting uses PCOS it most often means the full Rotterdam criteria are met and the metabolic tail (insulin resistance, lipid changes, fatty liver) is being actively considered. Neither label is wrong — but the second carries more clinical weight, and the move from one to the other usually happens once hormone tests and metabolic blood work are added to the ultrasound.

Most of the world, including the FOGSI guidelines used in Indian practice, diagnoses PCOS using the Rotterdam criteria of 2003. The criteria are deliberately simple — a woman is diagnosed with PCOS when any two of the following three features are present and other causes (thyroid disease, hyperprolactinemia, congenital adrenal hyperplasia, androgen-secreting tumours, Cushing syndrome) have been ruled out.

The first criterion is oligo or anovulation — irregular or absent periods, typically defined as cycles longer than 35 days or fewer than 8 cycles a year, that reflect the underlying failure of ovulation. The second is clinical or biochemical hyperandrogenism — either visible signs such as moderate-to-severe acne, hirsutism on the upper lip, chin, chest, abdomen or back, and androgenic hair thinning at the crown, or raised serum testosterone or free androgen index on blood testing. The third is polycystic ovaries on ultrasound, defined as 12 or more antral follicles per ovary measuring 2 to 9 mm, or an ovarian volume above 10 ml, on a transvaginal scan (or transabdominal in unmarried adolescents).

Two of three is enough. A woman with irregular periods and visible hirsutism has PCOS even if the ultrasound looks normal. A woman with irregular periods and classical polycystic ovaries on scan has PCOS even if her testosterone is normal. A woman with polycystic-appearing ovaries on scan but regular periods and no hyperandrogenism does not yet meet criteria — this is the picture most often labelled PCOD in everyday Indian practice. The Rotterdam framework is what converts an ultrasound finding into a syndrome diagnosis with treatment implications, and asking the gynec whether the criteria are formally met is one of the most useful questions a young Indian woman can take into a consultation.

India carries one of the highest PCOS burdens in the world. Community studies place the prevalence at roughly 10 to 25 percent of reproductive-age women depending on the criteria used and the population sampled, with urban rates running consistently higher than rural rates and a sharp rise across the last two decades that maps onto changing patterns of diet, weight, sleep and stress. Against that backdrop, the diagnostic system has not always kept pace.

A common Indian scenario looks like this — a young woman in her late teens or early twenties goes to a gynec or radiology centre with mild irregular periods or acne, gets a pelvic ultrasound, the report says polycystic-appearing ovaries, and she walks out with PCOD written on the prescription pad. Hormones are not always tested. Metabolic blood work is not always done. The metabolic implications are not always discussed. She is told to lose weight and given a packet of OCP or metformin, and a label that may or may not match the Rotterdam picture follows her through every future medical interaction. Over-medicalisation is a real concern at one end and under-investigation at the other — and the same word PCOD often hides both.

The other half of the same story is the woman with the full PCOS picture — irregular cycles, visible hirsutism, weight in the central pattern, acanthosis nigricans at the neck — who has never had her fasting glucose, HOMA-IR or lipid profile checked and is unaware that her long-term risk of type 2 diabetes, fatty liver and cardiovascular disease is significantly elevated and largely modifiable. In her case, calling the condition PCOD without naming the metabolic syndrome attached to it lets the bigger long-term risk go unaddressed. The fix in both directions is the same — when a PCOD or PCOS label is given, the right next question is whether the Rotterdam criteria have been formally checked, whether the hormonal panel has been done and whether the metabolic blood work has been done.

At the bedside the two labels produce a very similar list of symptoms, which is part of why the distinction is so easily blurred. The dominant complaint in both is menstrual irregularity — cycles that come every 35 to 90 days rather than every 28 to 35, frequent missed months, very light periods that barely soil a pad, or occasional unpredictable heavy bleeds when the lining finally sheds. Anovulation is the underlying mechanism, and over months it produces the unopposed estrogen pattern that contributes to the longer-term endometrial risk discussed below.

Skin and hair changes are the next most visible cluster. Acne tends to be moderate to severe, sits on the jawline, chin and upper back rather than only the T-zone, flares around the cycle and resists the topical treatments that handle teenage acne well. Oily skin is the usual companion. Hirsutism — coarse dark hairs on the upper lip, chin, sideburn line, lower abdomen, around the nipples and on the lower back — is one of the more distressing visible features and is covered in detail in hirsutism excess facial body hair india. Paradoxically, the same androgen excess thins the hair on the scalp, particularly at the crown and the central parting, producing the female-pattern hair loss many women notice in their late twenties.

Weight tends to gain in the central pattern around the abdomen rather than evenly over the body, and weight loss is consistently harder than in women without PCOS because of the underlying insulin resistance. Acanthosis nigricans — velvety dark patches at the back of the neck, underarms, groin and knuckles — is a low-cost visible clue to insulin resistance and is one of the more reliable bedside signs that the picture is the full PCOS rather than PCOD alone. Subfertility or difficulty conceiving without intervention is common but very often treatable, and is discussed below. Mood changes — irritability around the cycle, low mood, anxiety and a higher background rate of depression — are reported by a meaningful proportion of women in both groups and deserve to be named at the consultation rather than dismissed as separate.

The single sharpest reason to take the PCOS label seriously rather than treating the picture as just irregular periods plus cysts is the metabolic spine that runs underneath the syndrome. Insulin resistance — in which the body's cells respond less well to insulin and the pancreas compensates by producing more of it — is present in 50 to 70 percent of Indian women with PCOS even when the body weight is not visibly raised, and it is the single biggest driver of the longer-term complications.

Type 2 diabetes is the most important downstream risk. Women with PCOS have a 3 to 7 times higher lifetime risk of developing type 2 diabetes than women of the same age and weight without PCOS, and that risk begins to climb in the twenties rather than only in midlife. A fasting glucose, a HbA1c and an oral glucose tolerance test where indicated should be part of the first PCOS work-up, not deferred to the future. Dyslipidemia — raised triglycerides and LDL cholesterol with low HDL — accompanies the insulin resistance and is the bridge to the longer-term cardiovascular risk, which runs 2 to 4 times higher in women with PCOS over the lifetime.

Non-alcoholic fatty liver disease (NAFLD) is now recognised as part of the metabolic syndrome of PCOS and is detectable on ultrasound at much younger ages than was previously thought. Obstructive sleep apnea runs 3 times higher in PCOS than in matched controls and contributes back into the insulin resistance loop. Hypertension and metabolic syndrome are common. Long term, the cumulative effect of chronic unopposed estrogen from anovulation raises the risk of endometrial cancer by roughly 3 times — which is the single strongest reason to either induce regular withdrawal bleeds with cyclical progestin or use combined oral contraceptive pills in women who do not need fertility, rather than allowing many months at a stretch without a period.

None of these risks is inevitable. The same lifestyle and medication strategies that address the period irregularity also reverse insulin resistance, lower lipids, reduce fatty liver and lower long-term cardiovascular and cancer risk — and the women who name the metabolic picture early and address it actively in their twenties and thirties consistently do best in the longer-term studies. The metabolic tail of PCOS is the part that PCOD as a label tends to hide, and bringing it back into view is the most important reason to push for the fuller work-up.

The Indian diagnostic pathway for PCOD and PCOS is short, stepwise and largely affordable at most labs. The first step is a careful history covering the age at first period, the average cycle length and regularity, the recent pattern of bleeds, weight changes, acne and hirsutism timeline, hair thinning, mood symptoms, sleep, family history of PCOS, type 2 diabetes and cardiovascular disease, fertility plans and current medications. A pelvic examination then looks for a bulky uterus, an adnexal mass and the velvety dark patches of acanthosis nigricans at the neck and underarms.

Imaging is the next step. A transvaginal ultrasound (TVS) is the first-line scan in any sexually active woman and costs roughly 500 to 2,500 rupees in India; a transabdominal scan is used instead in young unmarried women. The scan counts antral follicles per ovary (12 or more meets the Rotterdam ultrasound criterion), measures ovarian volume (above 10 ml meets the criterion), looks for the classic string-of-pearls peripheral distribution of follicles and rules out a structural cause for the irregular periods such as fibroids or a polyp.

Hormone testing comes next and is done ideally on day 2 to 5 of a spontaneous or progestin-induced bleed. The core panel — LH and FSH (with an LH to FSH ratio above 2 historically supportive of PCOS), total testosterone, sex hormone-binding globulin (SHBG) with a calculated free androgen index, DHEAS (to rule out an adrenal source), prolactin (to rule out a prolactinoma), TSH (to rule out thyroid disease) and 17-hydroxyprogesterone (to rule out congenital adrenal hyperplasia in selected cases) — costs roughly 1,500 to 4,000 rupees in private labs and is free or near-free at government teaching hospitals. AMH (anti-Mullerian hormone) is often raised in PCOS and is being increasingly used as a supportive marker, particularly when the ultrasound is borderline.

Metabolic testing is where the PCOD-versus-PCOS distinction is sharpest and is the step most often skipped. A fasting glucose, a fasting insulin (to calculate HOMA-IR as a measure of insulin resistance), an oral glucose tolerance test where indicated, HbA1c, a full lipid profile and a liver function test cost another 1,500 to 3,500 rupees end-to-end. Vitamin D, vitamin B12 and ferritin are often added in the Indian context because deficiency is so common and contributes to fatigue and mood symptoms. The combined work-up at a private lab usually comes in at 2,000 to 6,000 rupees end-to-end, is fully covered at government and teaching hospitals, and is reimbursable under most major health insurance plans. This is the package that converts a PCOD-on-ultrasound finding into a properly characterised PCOS diagnosis with a treatment plan that matches the actual biology.

Whichever label a woman is given, lifestyle is the foundation of PCOS care and the only intervention that addresses every part of the syndrome at once — the cycle irregularity, the hyperandrogenism, the insulin resistance, the lipid pattern, the fatty liver, the fertility difficulty and the mood symptoms. A modest sustained weight loss of 5 to 10 percent of body weight restores spontaneous ovulation in a meaningful proportion of women, lowers fasting insulin sharply and is often enough by itself to bring periods back into a regular pattern.

The eating pattern that helps most is a low-glycaemic Indian plate. The single biggest swap is moving the carbohydrate base from refined white rice and maida-based foods (white bread, parathas, biscuits, instant noodles, snacks) towards whole grains and millets — ragi, bajra, jowar, foxtail millet (thinai), little millet (samai) and brown or hand-pounded rice. Add generous portions of dal, chana, rajma and sprouts for protein, plenty of green leafy vegetables (palak, methi, drumstick leaves) and seasonal sabzi, curd or buttermilk for gut and metabolic health, and seasonal fruit at meals rather than between them. Pull back on processed sugar, sweet drinks, deep-fried snacks and packaged foods rather than eliminate them — the sustained pattern matters more than perfection in any single week.

Movement is the second pillar. 150 minutes a week of moderate aerobic activity — brisk walking, cycling, swimming, dancing — combined with two short strength sessions a week using bodyweight or light resistance, produces measurable drops in insulin resistance and waist circumference within 8 to 12 weeks. Yoga has a small but consistent benefit on PCOS cycle regularity and stress markers in Indian trials, and asanas such as Surya Namaskar, Bhujangasana, Setubandhasana and Baddha Konasana are commonly recommended. Sleep of 7 to 9 hours and stress management through pranayama, meditation or whatever practice the woman already uses are not optional add-ons — both directly modulate the cortisol-insulin axis that drives PCOS.

Two practical notes matter. First, weight loss is meaningfully harder in PCOS than in women without it, and the right metric is steady, sustainable change over 6 to 12 months rather than rapid drops that do not hold. Second, lifestyle and medication are partners rather than alternatives — many Indian women do best on lifestyle plus metformin or lifestyle plus a low-dose OCP in the first 12 months, with the medication doses reduced as the lifestyle gains hold. The fuller diet detail is covered in anti-pcos diet what actually works.

When lifestyle alone is not enough or when symptoms are significant from the first visit, the Indian medication ladder for PCOS is built around three goals — improving insulin sensitivity, regularising the cycle and protecting the endometrium, and addressing the visible androgenic features. Most women use one or two of the rungs at a time, and the combination changes over the years as priorities (cycle regularity now vs fertility later) shift.

Metformin sits at the base of the ladder and addresses the insulin resistance that drives much of the syndrome. The usual starting dose is 500 mg once a day taken with the largest meal, gradually built up over 2 to 4 weeks to 500 to 1,000 mg twice a day to limit gut side effects (loose stools, nausea, metallic taste in the mouth) which usually settle within the first month. Metformin improves cycle regularity in many women, restores ovulation in a meaningful proportion and meaningfully reduces the long-term progression to type 2 diabetes. The cost in India runs roughly 50 to 300 rupees a month and the medicine is widely available at Jan Aushadhi outlets at the lower end of that range.

Combined oral contraceptive pills are the second rung when the priority is cycle regularity, acne and hirsutism rather than insulin resistance, and they are the first-line hormonal option in women not currently trying to conceive. The pills used most commonly in Indian practice — Yasmin and Krimson 35 (drospirenone-based, with a useful anti-androgenic effect), Diane-35 (cyproterone-based, used short-term for moderate-to-severe hirsutism and acne) and Femilon (lower-dose estrogen for women who tolerate hormones less well) — produce predictable monthly withdrawal bleeds, lower circulating androgens by raising sex hormone-binding globulin, clear most of the acne and hirsutism over 3 to 6 cycles and protect the endometrium from the cancer risk of chronic unopposed estrogen. Cost runs 100 to 500 rupees a month depending on the brand. The contraindications and longer detail are covered in the broader PCOS treatment article — see pcos treatment options india.

Spironolactone (Aldactone) is added when hirsutism remains the dominant complaint despite an OCP, at doses of 50 to 200 mg a day, and produces visible improvement in facial and body hair within 6 to 9 months when paired with cosmetic measures such as laser hair reduction or threading. It is used with reliable contraception because of potential feminising effects on a male fetus. For women trying to conceive, ovulation induction with letrozole (an aromatase inhibitor) at 2.5 to 7.5 mg from day 2 to day 6 of the cycle is now the first-line agent in international and Indian guidelines, having shown better live birth rates than the older clomiphene citrate, particularly in women with higher BMI. Both cost 50 to 300 rupees a cycle and are widely available. IUI or IVF is the next rung when 3 to 6 cycles of letrozole have not worked. Ovarian drilling and bariatric surgery are reserved for very selected situations and are no longer first-line.

Fertility worry is the single most common reason young Indian women with a PCOD or PCOS label come back into a gynec OPD a few years after the first diagnosis, and the picture is far more hopeful than the early-twenties anxiety suggests. The overall message is straightforward — most women with PCOS who want to conceive eventually do, and the pathway is well-mapped and largely affordable in India.

The first step in many women is the same lifestyle work that addresses every other part of the syndrome. A 5 to 10 percent reduction in body weight restores spontaneous ovulation in a meaningful proportion of overweight women with PCOS, sometimes within 3 to 6 months, and can be enough by itself to allow natural conception. Even without weight loss, addressing insulin resistance with metformin and improving sleep and stress patterns can restore cycle regularity and ovulation in many women.

When spontaneous ovulation does not return, ovulation induction is the next step. Letrozole 2.5 to 7.5 mg from day 2 to day 6 of the cycle is now the first-line agent and produces ovulation in around 70 to 80 percent of women with PCOS and live birth rates around 25 to 30 percent per cycle, both higher than the older clomiphene citrate which remains a reasonable alternative at 50 to 100 mg on the same days. A cycle is monitored with a follicular-tracking ultrasound on day 10 to 12, costs roughly 500 to 1,500 rupees per scan, and most pregnancies in responding women happen within the first three to six cycles. Where letrozole or clomiphene alone is not enough, low-dose gonadotropin injections are added in the same monitored cycle. Intrauterine insemination (IUI) is reserved for couples with combined factors and costs roughly 8,000 to 25,000 rupees per cycle in India; IVF is the next step for non-responders and costs 1.5 to 3 lakh rupees per cycle in private centres and considerably less at government teaching hospitals.

Two practical points matter. First, ovulation induction in PCOS carries a small but real risk of ovarian hyperstimulation syndrome and of multiple pregnancy, which is why the cycles are monitored with ultrasound and why the doses are kept conservative. Second, women with PCOS who do conceive carry slightly higher rates of gestational diabetes, pregnancy-induced hypertension and preterm birth, which is why a planned pre-pregnancy visit and active glucose monitoring through pregnancy matter — the fuller picture is covered in pcos and pregnancy india.

The single best argument for properly distinguishing PCOS from a vaguer PCOD label is the size of the long-term complication picture and the degree to which it is preventable when addressed early. Type 2 diabetes is the headline. Women with PCOS have a 3 to 7 times higher lifetime risk than women of similar age and weight without PCOS, the risk starts to climb in the twenties rather than only at midlife, and a meaningful proportion of women are already in the prediabetes range by their thirties. Annual fasting glucose and HbA1c testing from the time of diagnosis, lifestyle changes and metformin where indicated together cut this risk substantially.

Cardiovascular disease runs 2 to 4 times higher in PCOS over the lifetime, driven by the combined effect of insulin resistance, raised triglycerides, low HDL, raised blood pressure and central obesity. Obstructive sleep apnea, which itself worsens insulin resistance and cardiovascular risk, runs around 3 times higher than in matched controls. Non-alcoholic fatty liver disease is now recognised as a frequent companion of PCOS and is detectable on ultrasound at much younger ages than was previously thought; lifestyle changes and weight loss reverse early NAFLD reliably.

Endometrial cancer is the gynaecological cancer risk most closely tied to PCOS and runs roughly 3 times higher over the lifetime. The mechanism is straightforward — when ovulation fails for months at a stretch, the endometrium is exposed to estrogen without the protective monthly shedding that progesterone produces, and over years that unopposed estrogen drives endometrial hyperplasia and in some women progression to cancer. The fix is also straightforward — either combined oral contraceptive pills or cyclical progestin (such as medroxyprogesterone 10 mg for 10 days every 1 to 3 months) given to induce a regular withdrawal bleed, both of which protect the endometrium effectively in women who go many months without periods.

Mental health needs the same active management as the physical complications. Depression, anxiety and disordered eating run higher in PCOS than in matched controls, and the body-image impact of hirsutism, weight and acne is real and deserves to be named at the consultation rather than dismissed as separate. Counselling support is part of good PCOS care, and the iCall helpline (9152987821) is one of the free, confidential resources available across India for women who want to talk to someone confidentially before deciding on therapy.

Many Indian women approach PCOS through a combination of conventional medicine and traditional practice, and the right framing matters. Conventional medical care — lifestyle, metformin, hormonal options, ovulation induction where needed and structured monitoring of the metabolic risks — is the foundation and is the part with the strongest evidence base. Traditional and complementary practices sit alongside that foundation and can genuinely help with stress, sleep, mood and cycle regularity when used responsibly.

Yoga has the strongest evidence base of the complementary options. Indian trials have shown small but consistent improvements in cycle regularity, androgen markers, insulin sensitivity and mood with regular yoga practice. Surya Namaskar as a daily 10 to 15 minute sequence, gentler asanas such as Bhujangasana, Setubandhasana, Baddha Konasana and Supta Baddha Konasana, and pranayama practices such as Anulom Vilom and Bhramari are commonly used. Yoga is best framed as a free, sustainable layer on top of the lifestyle plan rather than as an alternative to it.

Ayurvedic herbal preparations are widely used in Indian PCOS care and the evidence picture is mixed. Some single-herb preparations (such as cinnamon and fenugreek) have small randomised trial evidence for insulin sensitivity benefit. Formulations sold for PCOS often contain multiple ingredients without consistent dosing and without rigorous trial evidence. The safest approach is to discuss any Ayurvedic preparation with the treating gynec and the Ayurvedic practitioner together, to avoid herb-drug interactions (particularly with metformin, OCPs and any thyroid medication) and to make sure the preparation is being added to and not used in place of conventional care.

Two cautions matter. First, no traditional or alternative approach reliably reverses PCOS on its own when the metabolic syndrome is present, and waiting for an alternative cure while the long-term diabetes and cardiovascular risk goes unaddressed is the most common way good intentions cause harm. Second, weight-loss and PCOS cure programmes that promise rapid results outside the conventional framework should be looked at with caution — the evidence base for sustained PCOS improvement is built around the lifestyle, medication and monitoring pathway described above, and shortcuts that bypass it rarely hold.

• Myth: PCOD and PCOS are completely different conditions. Fact: they sit along the same spectrum — PCOD in everyday Indian use most often refers to polycystic-appearing ovaries on ultrasound with milder symptoms, while PCOS describes the full syndrome that includes hormonal and metabolic features; the right next step in either case is to check whether the Rotterdam criteria are met and to do the hormonal and metabolic work-up.
• Myth: PCOD means the ovaries have to be removed. Fact: ovarian removal is not part of PCOS or PCOD care in any modern guideline; the older operation of ovarian wedge resection was replaced first by laparoscopic ovarian drilling, which itself is now rarely needed because lifestyle, metformin, hormonal options and letrozole address the syndrome more safely.
• Myth: a PCOS diagnosis makes infertility certain. Fact: most Indian women with PCOS who want to conceive eventually do — lifestyle changes restore ovulation in many, letrozole or clomiphene-based ovulation induction works in 70 to 80 percent of women, and IUI or IVF cover most of the remainder; PCOS is one of the most treatable causes of subfertility.
• Myth: home remedies and Ayurvedic preparations alone can cure PCOS. Fact: lifestyle is the foundation and traditional practices can genuinely help with stress, sleep and mood, but no preparation reliably reverses the syndrome on its own when the metabolic features are present; the safest plan is conventional care plus complementary practices used together, with the gynec aware of both.
• Myth: marriage or pregnancy cures PCOS. Fact: neither marriage nor pregnancy alters the underlying biology of PCOS; the cycle often improves around childbearing because of the prolonged hormonal stability of pregnancy and breastfeeding, but the syndrome returns once cycles restart and the lifelong metabolic risk continues regardless, which is why the lifestyle and monitoring plan should not be put on pause around either life event.
• Myth: type 2 diabetes is inevitable with PCOS. Fact: the lifetime risk is meaningfully raised but the risk is largely modifiable — sustained 5 to 10 percent weight loss, regular movement, sleep, stress management and metformin where indicated together reduce the progression rate substantially, and women who name the metabolic risk early in their twenties and address it consistently do markedly better than women who address it only after diagnosis of diabetes.